Sign in
CompletedNo phase

Visual and Patient-Reported Outcomes After Bilateral Non-Diffractive EDOF IOL Implantation

Key facts

Who runs it
Benha University
Where
Egypt1 site in 1 countryChoose a country to see its sites
Trial code
Status
Completed
People taking part
30 people enrolled
Started
3 Jan 2025
Ended
31 Jan 2025
Type of study
Interventional
Treatments tested
  • AcrySof IQ Vivity EDOF Intraocular Lens
Record updated
9 March 2026

Who can take part

Age
40 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 12 criteriaShow less

Who can take part

  • Age-related cataract requiring bilateral phacoemulsification
  • Corneal astigmatism ≤1.0 diopter
  • Desire for postoperative spectacle independence
  • Age ≥40 years
  • Ability and willingness to provide written informed consent

Who cannot take part

  • Previous ocular surgery in either eye
  • Systemic conditions likely to affect vision or surgical outcomes
  • Glaucoma
  • Macular degeneration
  • Corneal pathology
  • Any ocular comorbidity that may affect visual outcomes
  • Inability to comply with postoperative follow-up visits or study assessments

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

This study evaluates visual outcomes and patient-reported satisfaction following bilateral cataract surgery using a non-diffractive extended depth-of-focus (EDOF) intraocular lens (AcrySof IQ Vivity). The purpose of the study is to assess distance, intermediate, and near visual acuity, refractive accuracy, contrast sensitivity, spectacle independence, and the presence of photic phenomena after implantation. Thirty patients undergoing bilateral phacoemulsification will be enrolled. Participants will be evaluated at 1 and 3 months postoperatively.

The group in the trial

  • Bilateral Non-Diffractive EDOF IOL ImplantationTreatment being tested

    All participants underwent standard bilateral phacoemulsification cataract surgery with implantation of the AcrySof IQ Vivity non-diffractive extended depth-of-focus (EDOF) intraocular lens in both eyes. Target refraction was emmetropia. Postoperative care included a 4-week taper of combined topical antibiotic-steroid drops. Visual acuity, intermediate and near vision, spectacle independence, patient satisfaction, and photic phenomena were assessed at 1 and 3 months postoperatively.

    Treatment: AcrySof IQ Vivity EDOF Intraocular Lens

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Visual and Patient-Reported Outcomes Following Bilateral Implantation of Non-Diffractive Extended Depth-of-Focus Intraocular Lenses in Patients Undergoing Cataract Surgery
Record updated
9 March 2026